Skip to main content
×
×
Home

Alzheimer's disease: The amyloid hypothesis on trial

  • Judith R. Harrison (a1) and Michael J. Owen (a1)
Summary

The pathogenesis of Alzheimer's disease is complex. The amyloid hypothesis has directed research efforts for many years, but it has recently been questioned after failed drug trials. Here, we review the evidence for and against and suggest that it might be premature to abandon the amyloid hypothesis.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Alzheimer's disease: The amyloid hypothesis on trial
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Alzheimer's disease: The amyloid hypothesis on trial
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Alzheimer's disease: The amyloid hypothesis on trial
      Available formats
      ×
Copyright
Corresponding author
Judith R. Harrison, MRC Centre for Neuropsychiatric Genetics and Genomics, Institute of Psychological Medicine and Clinical Neurosciences, Cardiff University School of Medicine, Maindy Road, Cathays, Cardiff CF24 4HQ, UK. Email: harrisonjr1@cardiff.ac.uk
Footnotes
Hide All

Declaration of interest

None.

Footnotes
References
Hide All
1 Hardy, JA, Higgins, GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992; 256: 184–5.
2 Drachman, DA. The amyloid hypothesis, time to move on: amyloid is the downstream result, not cause, of Alzheimer's disease. Alzheimers Dement 2014; 10: 372–80.
3 Selkoe, DJ. The molecular pathology of Alzheimer's disease. Neuron 1991; 6: 487–98.
4 Hardy, J, Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 1991; 12: 383–8.
5 Tanzi, RE. The genetics of Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: a006296.
6 Sambamurti, K, Vasudevaraju, P, Mintzer, J, Bachman, D, Granholm, C. Can the failure of Alzheimer's disease clinical trials be stepping stones to ultimate success: is the amyloid hypothesis discredited by animal models. J Alzheimers Dis Parkinsonism 2012; 2: e115.
7 Jack, CR, Knopman, DS, Jagust, WJ, Shaw, LM, Aisen, PS, Weiner, MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119–28.
8 Rodrigue, KM, Kennedy, KM, Devous, MD, Rieck, JR, Hebrank, AC, Diaz-Arrastia, R, et al. β-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology 2012; 78: 387–95.
9 Braak, H, Braak, E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18: 351–7.
10 Jack, CR, Knopman, DS, Jagust, WJ, Petersen, RC, Weiner, MW, Aisen, PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207–16.
11 Karran, E, Mercken, M, De Strooper, B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011; 10: 698712.
12 Harold, D, Abraham, R, Hollingworth, P, Sims, R, Gerrish, A, Hamshere, ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41: 1088–93.
13 Doody, RS, Raman, R, Farlow, M, Iwatsubo, T, Vellas, B, Joffe, S, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med 2013; 369: 341–50.
14 Gilman, S, Koller, M, Black, RS, Jenkins, L, Griffith, SG, Fox, NC, et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64: 1553–62.
15 Karran, E, Hardy, J. A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol 2014; 76: 185205.
16 Toyn, JH, Ahlijanian, MK. Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid-β. Alzheimers Res Ther 2014; 6: 14.
17 Sperling, RA, Aisen, PS, Beckett, LA, Bennett, DA, Craft, S, Fagan, AM, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging–Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280–92.
18 Hyman, BT, Sorger, P. Failure analysis of clinical trials to test the amyloid hypothesis. Ann Neurol 2014; 76: 159–61.
19 Choi, SH, Kim, YH, Hebisch, M, Sliwinski, C, Lee, S, D'Avanzo, C, et al. A three-dimensional human neural cell culture model of Alzheimer/'s disease. Nature 2014; 515: 274–8.
20 Vellas, B, Carrillo, MC, Sampaio, C, Brashear, HR, Siemers, E, Hampel, H, et al. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement 2013; 9: 438–44.
21 Sperling, RA, Rentz, DM, Johnson, KA, Karlawish, J, Donohue, M, Salmon, DP, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med 2014; 6: 228fs13.
22 Mullard, A. Sting of Alzheimer's failures offset by upcoming prevention trials. Nat Rev Drug Discov 2012; 11: 657–60.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The British Journal of Psychiatry
  • ISSN: 0007-1250
  • EISSN: 1472-1465
  • URL: /core/journals/the-british-journal-of-psychiatry
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 136 *
Loading metrics...

Abstract views

Total abstract views: 380 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 23rd June 2018. This data will be updated every 24 hours.

Alzheimer's disease: The amyloid hypothesis on trial

  • Judith R. Harrison (a1) and Michael J. Owen (a1)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *